Brief: MaaT Pharma Announces Positive Outcomes From Final DSMB Meeting For Phase 3 Clinical Trial Evaluating MaaT013 In Acute Graft-Versus-Host Disease
18/03/2025 18:32
March 18 (Reuters) - Maat Pharma SA MAAT.PA: MAAT PHARMA ANNOUNCES POSITIVE OUTCOMES FROM FINAL DSMB MEETING FOR PIVOTAL PHASE 3 CLINICAL TRIAL EVALUATING MAAT013 IN ACUTE GRAFT-VERSUS-HOST DISEASE MAAT PHARMA SA - PLANS EMA SUBMISSION IN JUNE 2025 Source text: ID:nBw5W6748a Further company coverage: MAAT.PA (((( Reuters.Briefs@thomsonreuters.com ;));))
Recent news on Maat Pharma SA
See all newsBrief: MaaT Pharma Says FDA Indicates No Additional Nonclinical Studies Required For MaaT034 Safety
France's MaaT Pharma H1 operating loss widens on higher R&D costs
Brief: MaaT Pharma SA Receives 'Negative Trend' Opinion For Upcoming June CHMP Vote For MaaT013 (Xervyteg)
France's MaaT Pharma 2025 revenue rises 40.7% but misses expectations
Brief: MaaT Pharma Says Xervyteg Under EMA Review, Decision Expected In H2 2026